KYTXKyverna Therapeutics, Inc.

Nasdaq kyvernatx.com


$ 7.81 $ 0.31 (4.13 %)    

Monday, 01-Jul-2024 15:59:53 EDT
QQQ $ 481.74 $ 2.81 (0.59 %)
DIA $ 391.56 $ 0.33 (0.08 %)
SPY $ 545.33 $ 1.12 (0.21 %)
TLT $ 90.13 $ -1.58 (-1.73 %)
GLD $ 215.59 $ 0.56 (0.26 %)
$ 7.81
$ 7.45
$ 0.00 x 0
$ 0.00 x 0
$ 7.42 - $ 8.00
$ 6.75 - $ 35.06
478,959
na
185.52M
$ -0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a dev...

Core News & Articles

Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option aft...

 why-kyverna-therapeutics-stock-is-sinking

Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. ...

Core News & Articles

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate o...

Core News & Articles

Financial Results for the Year Ended December 31, 2023For the year ended December 31, 2023, the company reported a net loss of ...

Core News & Articles

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti C...

Core News & Articles

JP Morgan initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight rating and announces Price Target of $39.

Core News & Articles

Morgan Stanley analyst Michael Ulz initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight rating and ann...